Optimizing Treatment Outcomes in Advanced NSCLC with Concurrent Biomarker Testing - Episode 5

Biomarker Testing in Early-Stage NSCLC

June 4, 2024

Zofia Piotrowska, MD, MHS, Martin Dietrich, MD, PhD

Medical experts recommend that EGFR, ALK, and PD-L1 testing be performed as reflex tests for patients with early-stage non-small cell lung cancer to inform personalized treatment strategies.

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time 0:00

EP. 1: Optimizing NSCLC Patient Outcomes Through Concurrent Biomarker Testing

EP. 2: Concurrent NSCLC Biomarker Testing at Diagnosis

EP. 3: NCCN Guidelines: Optimizing NSCLC Treatment with Concurrent Biomarker Testing

EP. 4: Improving Time-to-Treatment for Patients With Non-Small Cell Lung Cancer

Now Viewing

EP. 5: Biomarker Testing in Early-Stage NSCLC

EP. 6: Reflex Testing for Patients with Suspected Lung Cancer

EP. 7: Challenges of NSCLC Biomarker Testing in Clinical Practice

EP. 8: Overcoming Barriers to NSCLC Biomarker Testing

EP. 9: Key Takeaways for Concurrent Biomarker Testing in NSCLC

What do available data show regarding the impact of concurrent testing on 1L therapy in advanced NSCLC? (Brief high-level overview only)
1. Raez, et al. Clin Lung Cancer, 2023
2. ACCELERATE – Garcia-Pardo, et al. JAMA Netw Open, 2023

Please comment on turnaround time for results, time to 1L treatment.